Skip to content
Menu

Merck & Co., Inc. MRK

Full chart Compare
Set alert

Price alert · MRK

All alert types
133.72 USD +0.91 (+0.69%)

Regular-session close

133.76 +0.04 +0.03%

After hours · Nov 20, 7:55 PM ET

133.11 Day range 137.17
94.97 52-week range 156.45
YTD
+27.04%
1 year
+40.80%

5D -14.97 (-10.06%)

140150MonTueWedThuFri133.90
Market cap
329.65B
Revenue (ttm)
67.38B
Profit margin
3.64%
EPS (ttm)
0.99
Shares out
2.47B
P/E ratio
135.07
Forward P/E
14.93
Dividend
3.52 (2.65%)
Ex-dividend date
Dec 15, 2026
YTD return
+27.04%
1-year return
+40.80%
Volume
15.61M
Avg volume
9.82M
Open
134.33
Previous close
132.81
Day's range
133.11 – 137.17
52-week range
94.97 – 156.45
Beta
0.12
Analysts
Buy
Price target
161.53 (+20.8%)
Earnings date
Feb 2, 2027
50-day average
145.48

Key statistics

200-day average
129.15
Enterprise value
371.72B
PEG ratio
3.33
Price / sales
4.90
Price / book
7.36
Payout ratio
343.43%
Revenue growth
4.70%
Free cash flow
14.02B
Total cash
9.65B
Total debt
53.90B
Return on equity
5.06%
Short % of float
1.08%

Fundamental scorecard

15 of 25 checks passed on MRK’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 1 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 3 of 5
  • Dividend 4 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
MRK Revenue — quarterly 18.09B
MRK Net income — quarterly 5.07B
MRK EPS — quarterly 2.05

Earnings

MRK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 2, 2027Dec 30, 20261.78———
Oct 29, 2026Sep 30, 20262.092.49+0.40+19.14%
Aug 4, 2026Jun 30, 2026-0.27049-0.13+0.14+51.94%
Apr 30, 2026Mar 31, 2026-1.47-1.28+0.19+12.93%
Feb 3, 2026Dec 31, 20252.012.04+0.03+1.49%
Oct 30, 2025Sep 30, 20252.362.58+0.22+9.32%

Upgrades / downgrades

MRK analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026Freedom BrokermainHoldHold
Nov 2, 2026Cantor FitzgeraldmainNeutralNeutral
Oct 30, 2026JP MorganmainOverweightOverweight
Oct 30, 2026RBC CapitalmainSector PerformSector Perform
Oct 30, 2026GuggenheimmainBuyBuy
Oct 26, 2026BarclaysmainOverweightOverweight

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
merck.com

News

Your note

Sign in to keep a note on MRK — it syncs with the Stock Master app.

Insider holders

MRK insider holders
InsiderRelationLatest transactionDateShares held
CHATTOPADHYAY SANATOfficerConversion of Exercise of derivative securityApr 28, 2026200,675
DAVIS ROBERT MChief Executive OfficerConversion of Exercise of derivative securityApr 28, 2026450,351
DELUCA RICHARD ROBERT JR.OfficerSaleNov 11, 2026114,291
GUINDO CHIRFIOfficerSaleAug 12, 202636,613
LI DEAN YOfficerConversion of Exercise of derivative securityApr 28, 202694,431
LITCHFIELD CAROLINEChief Financial OfficerConversion of Exercise of derivative securityApr 28, 202692,300

Institution ownership

MRK institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.25%228,073,24430.54BSep 29, 2026
Vanguard Capital Management LLC6.55%161,513,46121.63BSep 29, 2026
State Street Corporation4.93%121,422,39216.26BSep 29, 2026
Wellington Management Group, LLP2.91%71,664,5419.60BSep 29, 2026
Vanguard Portfolio Management LLC2.76%68,109,8999.12BSep 29, 2026
Geode Capital Management, LLC2.50%61,565,7028.24BSep 29, 2026

Fund ownership

MRK fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%78,411,37410.50BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.60%63,996,8848.57BJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF1.47%36,188,6064.85BAug 30, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%32,874,3674.40BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%32,063,2794.29BSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%30,514,3124.09BSep 29, 2026